Wall Street brokerages predict that Fate Therapeutics Inc (NASDAQ:FATE) will announce ($0.25) earnings per share for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for Fate Therapeutics’ earnings, with estimates ranging from ($0.27) to ($0.21). Fate Therapeutics reported earnings of ($0.21) per share in the same quarter last year, which indicates a negative year over year growth rate of 19%. The company is scheduled to report its next quarterly earnings report on Thursday, March 15th.
According to Zacks, analysts expect that Fate Therapeutics will report full year earnings of ($0.98) per share for the current year, with EPS estimates ranging from ($1.00) to ($0.94). For the next year, analysts expect that the company will report earnings of ($0.87) per share, with EPS estimates ranging from ($1.01) to ($0.72). Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that cover Fate Therapeutics.
Fate Therapeutics (NASDAQ:FATE) last posted its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($0.26) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by ($0.01). Fate Therapeutics had a negative return on equity of 64.55% and a negative net margin of 935.09%. The firm had revenue of $1.03 million for the quarter, compared to analysts’ expectations of $0.95 million. The company’s quarterly revenue was up .0% on a year-over-year basis.
In other news, General Counsel Cindy Tahl sold 8,091 shares of the company’s stock in a transaction that occurred on Monday, October 16th. The stock was sold at an average price of $3.85, for a total value of $31,150.35. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Daniel D. Shoemaker sold 13,225 shares of the company’s stock in a transaction that occurred on Monday, October 16th. The shares were sold at an average price of $3.87, for a total value of $51,180.75. The disclosure for this sale can be found here. 10.88% of the stock is owned by corporate insiders.
Hedge funds have recently bought and sold shares of the company. Hochman Cole Investment Advisors Inc. purchased a new stake in shares of Fate Therapeutics in the third quarter valued at approximately $158,000. New York State Common Retirement Fund purchased a new stake in shares of Fate Therapeutics in the second quarter valued at approximately $131,000. Rhumbline Advisers acquired a new position in Fate Therapeutics in the second quarter valued at approximately $133,000. Russell Investments Group Ltd. acquired a new position in Fate Therapeutics in the third quarter valued at approximately $234,000. Finally, Schwab Charles Investment Management Inc. acquired a new position in Fate Therapeutics in the second quarter valued at approximately $214,000. Institutional investors and hedge funds own 49.85% of the company’s stock.
Fate Therapeutics (NASDAQ:FATE) traded up $0.21 during trading hours on Tuesday, reaching $7.01. The company’s stock had a trading volume of 427,494 shares, compared to its average volume of 560,800. Fate Therapeutics has a 52 week low of $2.52 and a 52 week high of $7.25. The company has a current ratio of 7.21, a quick ratio of 7.21 and a debt-to-equity ratio of 0.32. The stock has a market cap of $354.33, a price-to-earnings ratio of -7.38 and a beta of 1.52.
ILLEGAL ACTIVITY WARNING: “-$0.25 EPS Expected for Fate Therapeutics Inc (FATE) This Quarter” was first reported by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this piece of content on another website, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be viewed at https://sportsperspectives.com/2018/01/12/0-25-eps-expected-for-fate-therapeutics-inc-fate-this-quarter.html.
Fate Therapeutics Company Profile
Fate Therapeutics, Inc (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.